Additional clonal abnormalities in Philadelphia-positive ALL and CML demonstrate a different cytogenetic pattern at

Ulrike Bacher1, Torsten Haferlach, Wolfgang Hiddemann

  • 1Laboratory for Leukemia Diagnostics, Department for Internal Medicine III, Klinikum Grosshadern, Ludwig-Maximilians-University, Marchioninistrasse 15, D-81377 Munich, Germany. ulrike.bacher@med.uni-muenchen.de

Insights

Cytogenetic patterns in Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) and chronic myeloid leukemia (CML) differ significantly at diagnosis and during disease progression. Karyotype analysis helps distinguish CML blast crisis from Ph+ ALL.

Area of Science:

  • Hematology
  • Oncology
  • Cytogenetics

Background:

  • Philadelphia translocation (Ph+) is a hallmark of certain leukemias, including Ph+ acute lymphoblastic leukemia (ALL) and chronic myeloid leukemia (CML).
  • Cytogenetic heterogeneity is observed in these Ph+ leukemias, necessitating detailed investigation.

Purpose of the Study:

  • To compare the cytogenetic patterns of Ph+ ALL and CML at diagnosis and during disease progression.
  • To determine if karyotype analysis can differentiate lymphoid blast crisis of CML from de novo Ph+ ALL.

Main Methods:

  • Karyotype analysis was performed on 154 patients with Ph+ ALL (at diagnosis or relapse) and 174 patients with CML (in various phases).
  • Comparative analysis of chromosomal aberrations and karyotype complexity was conducted.

Main Results:

  • Ph+ ALL at diagnosis showed heterogeneous cytogenetic patterns with frequent numerical and structural aberrations.
  • CML at diagnosis typically presented with rare additional chromosomal changes.
  • Ph+ ALL progression to relapse involved increased aberrations, but the pattern remained similar.
  • CML progression to advanced phases was marked by new chromosomal changes and increased karyotype complexity.
  • Lymphoid blast crisis of CML exhibited distinct karyotypes compared to de novo Ph+ ALL.

Conclusions:

  • Cytogenetic patterns of Ph+ ALL and CML are distinct at diagnosis.
  • Ph+ ALL and CML follow different evolutionary pathways during disease progression or relapse.
  • Karyotype analysis is a valuable tool for discriminating between de novo lymphoid blast crisis of CML and de novo Ph+ ALL.

Related Concept Videos

Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...